Anson Funds Management LP purchased a new position in shares of Reshape Lifesciences Inc (NASDAQ:RSLS) in the fourth quarter, reports. The institutional investor purchased 219,016 shares of the medical device company’s stock, valued at approximately $324,000.

A number of equities analysts recently commented on the company. Zacks Investment Research upgraded Reshape Lifesciences from a “sell” rating to a “hold” rating in a report on Wednesday, January 17th. ValuEngine upgraded Reshape Lifesciences from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

Shares of Reshape Lifesciences Inc (NASDAQ RSLS) opened at $1.48 on Wednesday. Reshape Lifesciences Inc has a 1-year low of $1.23 and a 1-year high of $7.30. The stock has a market capitalization of $44.34, a P/E ratio of -0.25 and a beta of 2.68.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at

Reshape Lifesciences Company Profile

ReShape Lifesciences Inc, formerly EnteroMedics Inc, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.

Want to see what other hedge funds are holding RSLS? Visit to get the latest 13F filings and insider trades for Reshape Lifesciences Inc (NASDAQ:RSLS).

Receive News & Ratings for Reshape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reshape Lifesciences and related companies with's FREE daily email newsletter.